Epigenetic silencing of interferon-κ in human papillomavirus type 16-positive cells

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8718-8725

  Rincon Orozco, Bladimiro ^a   Halec, Gordana ^b   Rosenberger, Simone ^a   Muschik, Dorothea ^a   Nindl, Ingo ^a   Bachmann, Anastasia ^a   Ritter, Tina Maria ^a   Dondog, Bolormaa ^c   Ly, Regina ^a   Bosch, Franz X ^b   Zawatzky, Rainer ^a   Rösl, Frank ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON KAPPA; INTERFERON REGULATORY FACTOR; MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN E6; PROTEIN E7; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOLYSIS; DNA METHYLATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; VERRUCA VULGARIS; VESICULAR STOMATITIS;

BLOTTING, WESTERN; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON TYPE I; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 72249089735     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0550     Document Type: Article

References (50)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-350
2. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220:82-101.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998 (Pubitemid 35363648)
4. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2:59-65. (Pubitemid 37328808)
5. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol 2008; 6:132-142
6. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007;7:79-89. (Pubitemid 46345510)
7. Li S, Labrecque S, Gauzzi MC, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2and impairs Jak-STAT activation by interferon-α. Oncogene 1999;18:5727-5737 (Pubitemid 29507426)
8. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-2072
9. Bachmann A, Hanke B, Zawatzky R, et al. Disturbance of tumor necrosis factor α-mediated β interferon signaling in cervical carcinoma cells. J Virol 2002;76:280-291
10. Bachmann A, Zawatzky R, Rosl F. Genetic redundancy in human cervical carcinoma cells: identification of cells with "normal" properties. Int J Cancer 2007;120:2119-2126
11. Noppert SJ, Fitzgerald KA, Hertzog PJ. The role of type I interferons in TLR responses. Immunol Cell Biol 2007;85:446-457
12. Alsharifi M, Mullbacher A, Regner M. Interferon type I responses in primary and secondary infections. Immunol Cell Biol 2008;86:239-245
13. Buontempo PJ, Jubin RG, Buontempo CA, Wagner NE, Reyes GR, Baroudy BM. Antiviral activity of transiently expressed IFN-κ is cell-associated. J Interferon Cytokine Res 2006;26:40-52.
14. Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, et al. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene 2002;21:165-175 (Pubitemid 34102125)
15. Soto U, Denk C, Finzer P, Hutter KJ, zur Hausen H, Rosl F. Genetic complementation to non-tumorigenicity in cervical-carcinoma cells correlates with alterations in AP-1 composition. Int J Cancer 2000;86:811-817 (Pubitemid 30350196)
16. Soto U, Das BC, Lengert M, Finzer P, zur Hausen H, Rosl F. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-α mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene 1999;18:3187-3198
17. Sutherland E, Coe L, Raleigh EA. McrBC: a multisubunit GTP-dependent restriction endonuclease. J Mol Biol 1992;225:327-348
18. Karsai S, Abel U, Roesch-Ely M, et al. Comparison of p16 (INK4a) expression with p53 alterations in head and neck cancer by tissuemicroarray analysis. J Pathol 2007;211:314-322 (Pubitemid 46172707)
19. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006;8:907-922 (Pubitemid 43670834)
20. Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007;178:3186-3197 (Pubitemid 46333201)
21. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008;20:17-22.
22. Bose S, Banerjee AK. Innate immune response against nonsegmented negative strand RNA viruses. J Interferon Cytokine Res 2003;23:401-412 (Pubitemid 37034578)
23. Nusinzon I, Horvath CM. Positive and negative regulation of the innate antiviral response and β interferon gene expression by deacetylation.Mol Cell Biol 2006;26:3106-3113
24. ScheffnerM,Munger K, Byrne JC,Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991;88:5523-5527 (Pubitemid 21914777)
25. Badal S, Badal V, Calleja-Macias IE, et al. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 2004;324:483-492
26. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996;24:5064-5066
27. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008;26:535-584
28. Haller O, Stertz S, Kochs G. The Mx GTPase family of interferon-induced antiviral proteins. Microbes Infect 2007;9:1636-1643 (Pubitemid 350217083)
29. Meager A. Biological assays for interferons. J Immunol Methods 2002;261:21-36.
30. Munoz-Fontela C, Macip S, Martinez-Sobrido L, et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008;205:1929-1938
31. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-α/β revisited. Nat Rev Mol Cell Biol 2001;2:378-386 (Pubitemid 33674050)
32. Nakao Y, Yang X, Yokoyama M, et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410-1416 (Pubitemid 27196859)
33. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-935
34. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433-440 (Pubitemid 46816750)
35. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005; 15:490-495 (Pubitemid 41262404)
36. Wade PA. SWItching off methylated DNA. Nat Genet 2005;37:212-213
37. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004;23:138-149 (Pubitemid 38165754)
38. Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004;64:3871-3877 (Pubitemid 38697298)
39. De-Castro Arce J, Gockel-Krzikalla E, Rosl F. Retinoic acid receptor β silences human papillomavirus-18 oncogene expression by induction of de novo methylation and heterochromatinization of the viral control region. J Biol Chem 2007;282:28520-28529 (Pubitemid 47606007)
40. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006;25:349-360 (Pubitemid 44354220)
41. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998;17:1087-1095
42. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-1831
43. Chen J, Baig E, Fish EN. Diversity and relatedness among the type I interferons. J Interferon Cytokine Res 2004;24:687-698
44. Chang HM, Paulson M, Holko M, et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A 2004;101:9578-9583 (Pubitemid 38869278)
45. Kersh EN, Fitzpatrick DR,Murali-Krishna K, et al. Rapid demethylation of the IFN-γ gene occurs inmemory but not naive CD8 T cells. J Immunol 2006;176:4083-4093
46. Fahrner JA, Baylin SB. Heterochromatin: stable and unstable invasions at home and abroad. Genes Dev 2003;17:1805-1812
47. Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007;26:1650-1655
48. Pim D, Massimi P, Banks L. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 1997;15:257-264
49. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516-523
50. Chen HM, Tanaka N, Mitani Y, et al. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci 2009;100:449-456